Immunocore Holdings PLC ADR
Suletud
28.18 -1.4
Ülevaade
Aktsiahinna muutus
24h
Min
27.44
Max
28.45
Sissetulek | 43M 13M |
|---|---|
Müük | 29M 107M |
Aktsiakasum | 0.25 |
Kasumimarginaal | 12.139 |
Töötajad | 524 |
EBITDA | 16M 8.2M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +126.46% upside |
Järgmine tulemuste avaldamine | 6. aug 2026 |
|---|
Turukapital | 32M 1.5B |
|---|---|
Eelmine avamishind | 29.58 |
Eelmine sulgemishind | 28.18 |
Immunocore Holdings PLC ADR Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Immunocore Holdings PLC ADR Prognoos
Hinnasiht
By TipRanks
126.46% tõus
12 kuu keskmine prognoos
Keskmine 65.13 USD 126.46%
Kõrge 100 USD
Madal 33 USD
Põhineb 9 Wall Streeti analüütiku instrumendi Immunocore Holdings PLC ADR 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Immunocore Holdings PLC ADR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
